Highlights
Pelvic exenteration (PE) provided meaningful long-term survival in a highly selected cohort of patients with recurrent cervical cancer, with five-year overall survival of 46% and cancer-specific survival of 52%.
The procedure remained highly morbid: 53% of patients experienced major postoperative complications within 90 days, and 4% died postoperatively.
A recurrence-free interval of more than 12 months between primary chemoradiation and PE was independently associated with better survival, with a hazard ratio of 0.38 (95% CI 0.16-0.87).
Among long-term survivors, standard patient-reported outcome measures suggested broadly acceptable global quality of life, but in-depth interviews uncovered enduring burdens related to ostomies, fatigue, pain, sexuality, body image, and social participation.
Background
Pelvic exenteration is one of the most radical operations in oncologic surgery. Developed as a salvage procedure for centrally recurrent pelvic malignancies, it remains one of the few potentially curative options for selected patients with recurrent cervical cancer after prior radiotherapy or chemoradiation. Yet the operation carries profound consequences: resection may involve the bladder, rectum, reproductive organs, and pelvic soft tissues, frequently resulting in permanent urinary and fecal diversion. The stakes are therefore unusually high, balancing a chance of cure against major perioperative risk and lifelong functional change.
In recurrent cervical cancer, treatment options are often constrained by prior radiation exposure and by anatomic extent of relapse. For small-volume central pelvic recurrence without unresectable sidewall involvement or distant metastases, PE can offer durable remission. However, the evidence base is limited by small series, single-center designs, and heterogeneous patient selection over long time spans. Outcomes beyond immediate oncologic endpoints have been especially underexplored. For many patients and clinicians, the central question is not only whether PE can prolong life, but what that life looks like years later.
The mixed-methods study by Valstad and colleagues addresses both sides of that question. Using a retrospective cohort of women treated at Oslo University Hospital over 25 years, the investigators examined survival and perioperative morbidity. They then paired these quantitative findings with a detailed survivorship assessment in long-term recurrence-free survivors using validated questionnaires and qualitative interviews. This combined approach is particularly valuable in PE, where conventional quality-of-life instruments may miss dimensions of bodily disruption, relational change, and practical adaptation that dominate daily life.
Study Design and Methods
Design and setting
This was a mixed-methods study from Oslo University Hospital including 55 patients treated with pelvic exenteration for recurring cervical cancer between 1995 and 2020. The oncologic component was retrospective. A nested survivorship substudy was performed in a subgroup of ten long-term, recurrence-free survivors.
Population
The main study population consisted of women undergoing PE for recurrent cervical cancer. The abstract specifies that the clinically important exposure of interest was the interval between primary chemoradiation and PE, analyzed as more than 12 months versus shorter intervals. The long-term survivorship subgroup had a median follow-up of 9 years after PE, with a range of 5 to 18 years.
Endpoints
Key oncologic endpoints included postoperative morbidity, 90-day mortality, overall survival, and cancer-specific survival. Major complications were defined as grade 3 or higher. The patient-reported outcomes component evaluated health-related quality of life (HRQoL), anxiety, and depression using validated instruments. Semi-structured interviews were analyzed with reflexive thematic analysis to identify experiential themes not fully captured by standardized questionnaires.
Why the mixed-methods approach matters
PE is a procedure in which numeric scores can be misleading if interpreted alone. A patient may report acceptable global functioning while simultaneously living with profound restrictions in sexuality, travel, intimacy, continence management, fatigue, or body image. By integrating validated questionnaires with qualitative interviews, the authors were able to test whether favorable aggregate HRQoL scores aligned with lived experience. That design choice is one of the study’s major strengths.
Key Findings
Perioperative morbidity remained substantial
The surgical burden was considerable. Major complications within 90 days occurred in 53% of patients, and postoperative mortality was 4%. These figures reinforce the reality that PE remains a high-risk operation even in experienced centers. For clinicians, these data are highly relevant during preoperative counseling: the procedure is potentially curative, but the immediate price of attempting cure is steep.
The abstract does not detail the specific complication spectrum, but historical PE series commonly report pelvic abscesses, wound breakdown, fistula formation, urinary tract complications, thromboembolism, bowel complications, and the need for reoperation. Given that this series spans 1995 to 2020, changes in perioperative care, reconstructive techniques, and critical care support may have influenced outcomes over time, though this cannot be fully assessed from the abstract alone.
Long-term survival was clinically meaningful
After a median follow-up of 14 years, five-year overall survival was 46%, and five-year cancer-specific survival was 52%. In a disease state where therapeutic options are limited and many patients have previously received definitive chemoradiation, these survival figures are notable. They support PE as a legitimate curative-intent strategy in carefully selected patients rather than a purely heroic intervention.
These findings are broadly consistent with prior institutional series reporting five-year survival in the range of roughly 20% to 60%, depending on patient selection, margin status, nodal disease, extent of recurrence, and center expertise. The present study adds particularly valuable long follow-up, reducing the concern that apparent disease control might merely reflect short surveillance windows.
A longer recurrence-free interval predicted better outcome
An interval of more than 12 months between primary chemoradiation and PE was independently associated with improved survival, with a hazard ratio of 0.38 (95% CI 0.16-0.87). Clinically, this suggests that tumors recurring after a longer disease-free interval may have a more favorable biology or may be more amenable to complete salvage resection.
This observation aligns with a broader oncologic principle: time to recurrence often acts as a surrogate for disease aggressiveness. In practical terms, recurrence-free interval can help frame multidisciplinary discussions alongside imaging findings, potential resectability, performance status, and absence of metastatic disease. Importantly, however, it should not be used in isolation. PE candidacy depends on anatomy and operability as much as on timing.
Standardized HRQoL appeared reassuring at first glance
Among the ten long-term, recurrence-free survivors, quantitative HRQoL data showed generally preserved global and functional scores. Anxiety and depression levels were low overall. This is an important message, because it suggests that some women who undergo PE can adapt over time and regain a meaningful level of overall functioning. It also counters simplistic assumptions that life after PE is uniformly intolerable.
At the same time, several domains reached clinical relevance for persistent impairment: social functioning, diarrhea, and financial difficulties. These areas are especially important because they often sit at the boundary between medicine and everyday life. Social function reflects more than symptom control; it reflects confidence, mobility, continence management, stigma, and energy. Financial distress may reflect disability, altered employment, travel needs, supply costs, or prolonged dependence on healthcare systems.
Qualitative interviews revealed what the questionnaires missed
The qualitative findings are arguably the most practice-changing aspect of the study. Despite relatively favorable questionnaire scores, interviews revealed substantial and persistent physical, practical, and relational challenges. Ostomies imposed major logistical and social burdens. Fatigue and pain continued to constrain daily life. Most participants reported permanent loss of sexual function and altered body image. These consequences were not trivial or transient; they remained salient years after surgery.
This discordance between standardized scores and narrative accounts is deeply instructive. A global HRQoL score may average out severe burdens if patients have adapted expectations, feel grateful for survival, or prioritize being alive over function. In survivorship research, this phenomenon is sometimes described as response shift: individuals recalibrate their internal standards after major illness. As a result, a patient can report acceptable overall quality of life while still enduring major losses in specific domains.
For PE survivors, practical adaptation itself may be labor-intensive. Ostomy care can affect travel, clothing choices, work routines, sleep, intimacy, and spontaneous social activity. Sexual dysfunction after radical pelvic surgery may involve anatomic loss, nerve injury, fibrosis, dyspareunia, vaginal shortening or absence, and profound identity disruption. These are areas where conventional cancer follow-up often remains underdeveloped.
Most survivors still considered PE worthwhile
One of the study’s most striking findings is that nearly all interviewed participants judged the surgery worthwhile despite its lasting sequelae. This underscores an ethically important point: severe morbidity does not automatically negate perceived value, particularly when patients understand the procedure as a chance for cure. However, this should not be misread as minimizing harm. Rather, it highlights the need for transparent counseling that respects both truths at once: PE can be life-saving, and PE can permanently change life.
Clinical Interpretation
This study supports PE as a valid salvage option for selected patients with recurrent cervical cancer, particularly when recurrence occurs after a longer interval from primary chemoradiation. The survival data are strong enough to justify serious consideration of surgery in appropriate candidates. At the same time, the morbidity profile remains formidable, and survivorship after PE must be framed as a long-term multidisciplinary issue rather than a purely surgical episode.
For gynecologic oncologists, several practical implications follow. First, patient selection remains central. Disease-free interval, imaging-based assessment of resectability, exclusion of distant disease, and likelihood of achieving negative margins remain critical determinants of benefit. Second, preoperative consent should move beyond generic statements about complications and include specific discussion of permanent ostomies, fatigue, chronic pain, sexual dysfunction, altered body image, dependence on appliances, and social limitations. Third, follow-up should not end with surveillance imaging. Long-term care should include stoma therapy, pain management, pelvic rehabilitation, sexual health counseling, psychosocial support, and attention to employment and financial toxicity.
The study also provides a useful caution for outcomes research. If clinicians rely only on standardized HRQoL instruments, they may underestimate lasting burdens after radical pelvic surgery. Mixed-methods assessment may therefore be particularly valuable in survivorship studies of highly morbid interventions, where adaptation can mask ongoing hardship in questionnaire-based summaries.
Strengths and Limitations
Strengths
The study has several notable strengths. It addresses an uncommon but clinically consequential procedure in a defined institutional cohort with very long follow-up. It reports both oncologic outcomes and survivorship experience, which are often separated in the literature. The use of validated patient-reported outcomes plus qualitative interviews gives the analysis unusual depth and captures dimensions of health that conventional surgical series often miss.
Limitations
Important limitations should temper interpretation. This was a single-center retrospective study with only 55 patients, limiting power and generalizability. Selection bias is unavoidable, particularly in a procedure offered only to highly selected candidates. Practice patterns, imaging, perioperative care, reconstructive methods, and supportive care likely evolved substantially between 1995 and 2020. The survivorship substudy included only ten recurrence-free long-term survivors, a group that may represent the most favorable adaptation profile and excludes those with recurrence, severe deterioration, or death. Quantitative HRQoL results from such a small sample should therefore be viewed as exploratory rather than definitive.
Another limitation is that the abstract does not report several factors that often drive prognosis after PE, including margin status, nodal involvement, type of exenteration, reconstruction strategy, or extent of sidewall disease. These variables would help clinicians better understand which patients derived the greatest benefit.
Relation to Existing Literature and Guidelines
Existing guideline frameworks, including National Comprehensive Cancer Network recommendations for recurrent cervical cancer, recognize pelvic exenteration as a potentially curative option for carefully selected patients with central pelvic recurrence after prior radiation-based treatment. The present study fits well within that paradigm, while contributing a more nuanced understanding of life after treatment.
Prior reviews and institutional series have repeatedly shown that complete resection, negative margins, absence of nodal or metastatic disease, and favorable disease distribution are among the strongest predictors of survival. The current report adds recurrence-free interval after primary chemoradiation as an independently associated prognostic variable, which may help refine discussions in tumor boards.
The survivorship findings are especially valuable because they resonate with broader literature showing that sexual dysfunction, altered body image, bowel and urinary consequences, and fatigue remain underrecognized after radical pelvic cancer treatment. The discrepancy between “acceptable” global quality of life and serious domain-specific suffering is not unique to PE, but it may be especially pronounced here.
Implications for Practice
Preoperative counseling
Counseling should explicitly cover both survival potential and likely life changes. Patients should understand the chances of major complications and perioperative death, the likelihood of permanent ostomies, the realistic possibility of chronic fatigue or pain, and the near-certainty of major effects on sexual function.
Multidisciplinary selection
Decision-making should involve gynecologic oncology, radiology, anesthesia, reconstructive or colorectal/urologic surgery as needed, stoma care specialists, psycho-oncology, and rehabilitation teams. Centralization to experienced centers is likely important.
Long-term survivorship care
Survivorship programs for PE should include structured assessment of ostomy function, mobility, pain, sexual health, intimate relationships, body image, social participation, and financial burden. Standard surveillance visits alone are insufficient.
Conclusion
This mixed-methods study reinforces pelvic exenteration as a high-risk but potentially curative salvage strategy for recurrent cervical cancer. In selected patients, long-term survival is meaningful, especially when recurrence occurs more than 12 months after primary chemoradiation. Yet survival statistics tell only part of the story. Even years later, many survivors live with major physical, social, sexual, and practical consequences that standardized quality-of-life instruments may understate. For clinicians, the message is clear: PE should be offered thoughtfully, counseled honestly, and followed by multidisciplinary long-term survivorship care that is as deliberate as the surgery itself.
Funding and Trial Registration
The abstract does not report a funding source. No ClinicalTrials.gov registration number is provided, which is consistent with the retrospective observational design and nested qualitative survivorship study.
References
Valstad H, Fauske L, Wang YY, Eyjólfsdóttir B, Kristensen GB, Skeie-Jensen T, Areklett EW, Lindemann K. Pelvic exenteration for cervical cancer – Oncologic outcome and long-term health-related quality of life, a mixed methods study. Gynecologic Oncology. 2026;210:183-192. PMID: 42263503.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Current version available at NCCN.org.
Shingleton HM, Soong SJ, Gelder MS, Hatch KD, Baker VV, Austin JM Jr. Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstetrics and Gynecology. 1989;73(6):1027-1034.
Marnitz S, Köhler C, Müller M, Behrens K, Hasenbein K, Schneider A. Indications for primary and secondary exenterations in patients with cervical cancer. Gynecologic Oncology. 2006;103(3):1023-1030.
Westin SN, Rallapalli V, Fellman B, Urbauer DL, Pal N, Frumovitz M, Ramirez PT, Euscher ED, Schmeler KM. Overall survival after pelvic exenteration for gynecologic malignancy. Gynecologic Oncology. 2014;134(3):546-551.
